General Information of the Ferroptosis Regulator (ID: REG20037)
Regulator Name hsa-miR-382-5p (miRNA)
Synonyms
hsa-miR-382-5p
    Click to Show/Hide
Gene Name hsa-miR-382-5p
Regulator Type miRNA
MiRBase ID MIMAT0000737
Sequence
GAAGUUGUUCGUGGUGGAUUCG

    Click to Show/Hide
Full List of the Ferroptosis Target of This Regulator and Corresponding Disease/Drug Response(s)
hsa-miR-382-5p can regulate the following target(s), and cause disease/drug response(s). You can browse detail information of target(s) or disease/drug response(s).
Browse Target
Browse Disease
Browse Drug
Cystine/glutamate transporter (SLC7A11) [Driver; Suppressor]
In total 2 item(s) under this target
Experiment 1 Reporting the Ferroptosis Target of This Regulator [1]
Target for Ferroptosis Suppressor
Responsed Disease Breast cancer ICD-11: 2C60
Responsed Drug Lidocaine Investigative
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Apoptosis hsa04210
Cell Process Cell ferroptosis
Cell apoptosis
Cell proliferation
Cell migration
Cell invasion
In Vitro Model
SK-OV-3 cells Ovarian serous cystadenocarcinoma Homo sapiens CVCL_0532
T-47D cells Invasive breast carcinoma Homo sapiens CVCL_0553
In Vivo Model
SPF-level male nude mice aged 56weeks and weighted around 20 g were purchased from Vitalriver (China). All mice were maintained in a 12-hour circadian rhythm, and had free access to water and food. Cancer cells were subcutaneously injected into the right flank of mice. Lidocaine was administrated to mice at a dose of 1.5 mg per kg injected through the vail tails. For control group, the mice were treated with saline. Tumor volume and mice body weight were monitored every 5 days.

    Click to Show/Hide
Response regulation The ovarian and breast cancer cell proliferation was suppressed while cell apoptosis was induced by lidocaine in vitro. Lidocaine attenuated invasion and migration of ovarian and breast cancer cells as well. Regarding the mechanism, lidocaine downregulated solute carrier family 7 member 11 (SLC7A11) expression by enhancing microRNA-382-5p (miR-382-5p) in the cells.
Experiment 2 Reporting the Ferroptosis Target of This Regulator [1]
Target for Ferroptosis Suppressor
Responsed Disease Ovarian cancer ICD-11: 2C73
Responsed Drug Lidocaine Investigative
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Apoptosis hsa04210
Cell Process Cell ferroptosis
Cell apoptosis
Cell proliferation
Cell migration
Cell invasion
In Vitro Model
SK-OV-3 cells Ovarian serous cystadenocarcinoma Homo sapiens CVCL_0532
T-47D cells Invasive breast carcinoma Homo sapiens CVCL_0553
In Vivo Model
SPF-level male nude mice aged 56weeks and weighted around 20 g were purchased from Vitalriver (China). All mice were maintained in a 12-hour circadian rhythm, and had free access to water and food. Cancer cells were subcutaneously injected into the right flank of mice. Lidocaine was administrated to mice at a dose of 1.5 mg per kg injected through the vail tails. For control group, the mice were treated with saline. Tumor volume and mice body weight were monitored every 5 days.

    Click to Show/Hide
Response regulation The ovarian and breast cancer cell proliferation was suppressed while cell apoptosis was induced by lidocaine in vitro. Lidocaine attenuated invasion and migration of ovarian and breast cancer cells as well. Regarding the mechanism, lidocaine downregulated solute carrier family 7 member 11 (SLC7A11) expression by enhancing microRNA-382-5p (miR-382-5p) in the cells.
Unspecific Target [Unspecific Target]
In total 1 item(s) under this target
Experiment 1 Reporting the Ferroptosis Target of This Regulator [2]
Responsed Disease Gastric cancer ICD-11: 2B72
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
Cell proliferation
Cell migration
Cell invasion
In Vitro Model
AGS cells Gastric adenocarcinoma Homo sapiens CVCL_0139
KATO III cells Gastric signet ring cell adenocarcinoma Homo sapiens CVCL_0371
MKN-1 cells Gastric carcinoma Homo sapiens CVCL_1415
HGC-27 cells Gastric carcinoma Homo sapiens CVCL_1279
In Vivo Model
Nude mice (5-week old; Shanghai SLAC Laboratory Animals, Shanghai, China) were arbitrarily divided into two groups (n = 5). AGS cells (1 x 106 ) stably expressing circ_0000190 were inoculated into the flank of the nude mice. Tumor volume was monitored every 4 d with the method of (length x width2 )/2. These mice were euthanized after 28-d inoculation.

    Click to Show/Hide
Response regulation Circ_0000190 overexpression inhibited the proliferation, migration and invasion and promoted Erastin- or ras selective lethal 3 (RSL3)-mediated ferroptosis in gastric cancer cells. And circ_0000190 suppressed GC progression via miR-382-5p-dependent regulation of ZNRF3.
Breast cancer [ICD-11: 2C60]
In total 1 item(s) under this disease
Experiment 1 Reporting the Ferroptosis-centered Disease Response [1]
Target Regulator hsa-miR-382-5p (miRNA) miRNA
Responsed Drug Lidocaine Investigative
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Apoptosis hsa04210
Cell Process Cell ferroptosis
Cell apoptosis
Cell proliferation
Cell migration
Cell invasion
In Vitro Model
SK-OV-3 cells Ovarian serous cystadenocarcinoma Homo sapiens CVCL_0532
T-47D cells Invasive breast carcinoma Homo sapiens CVCL_0553
In Vivo Model
SPF-level male nude mice aged 56weeks and weighted around 20 g were purchased from Vitalriver (China). All mice were maintained in a 12-hour circadian rhythm, and had free access to water and food. Cancer cells were subcutaneously injected into the right flank of mice. Lidocaine was administrated to mice at a dose of 1.5 mg per kg injected through the vail tails. For control group, the mice were treated with saline. Tumor volume and mice body weight were monitored every 5 days.

    Click to Show/Hide
Response regulation The ovarian and breast cancer cell proliferation was suppressed while cell apoptosis was induced by lidocaine in vitro. Lidocaine attenuated invasion and migration of ovarian and breast cancer cells as well. Regarding the mechanism, lidocaine downregulated solute carrier family 7 member 11 (SLC7A11) expression by enhancing microRNA-382-5p (miR-382-5p) in the cells.
Ovarian cancer [ICD-11: 2C73]
In total 1 item(s) under this disease
Experiment 1 Reporting the Ferroptosis-centered Disease Response [1]
Target Regulator hsa-miR-382-5p (miRNA) miRNA
Responsed Drug Lidocaine Investigative
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Apoptosis hsa04210
Cell Process Cell ferroptosis
Cell apoptosis
Cell proliferation
Cell migration
Cell invasion
In Vitro Model
SK-OV-3 cells Ovarian serous cystadenocarcinoma Homo sapiens CVCL_0532
T-47D cells Invasive breast carcinoma Homo sapiens CVCL_0553
In Vivo Model
SPF-level male nude mice aged 56weeks and weighted around 20 g were purchased from Vitalriver (China). All mice were maintained in a 12-hour circadian rhythm, and had free access to water and food. Cancer cells were subcutaneously injected into the right flank of mice. Lidocaine was administrated to mice at a dose of 1.5 mg per kg injected through the vail tails. For control group, the mice were treated with saline. Tumor volume and mice body weight were monitored every 5 days.

    Click to Show/Hide
Response regulation The ovarian and breast cancer cell proliferation was suppressed while cell apoptosis was induced by lidocaine in vitro. Lidocaine attenuated invasion and migration of ovarian and breast cancer cells as well. Regarding the mechanism, lidocaine downregulated solute carrier family 7 member 11 (SLC7A11) expression by enhancing microRNA-382-5p (miR-382-5p) in the cells.
Gastric cancer [ICD-11: 2B72]
In total 1 item(s) under this disease
Experiment 1 Reporting the Ferroptosis-centered Disease Response [2]
Target Regulator hsa-miR-382-5p (miRNA) miRNA
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
Cell proliferation
Cell migration
Cell invasion
In Vitro Model
AGS cells Gastric adenocarcinoma Homo sapiens CVCL_0139
KATO III cells Gastric signet ring cell adenocarcinoma Homo sapiens CVCL_0371
MKN-1 cells Gastric carcinoma Homo sapiens CVCL_1415
HGC-27 cells Gastric carcinoma Homo sapiens CVCL_1279
In Vivo Model
Nude mice (5-week old; Shanghai SLAC Laboratory Animals, Shanghai, China) were arbitrarily divided into two groups (n = 5). AGS cells (1 x 106 ) stably expressing circ_0000190 were inoculated into the flank of the nude mice. Tumor volume was monitored every 4 d with the method of (length x width2 )/2. These mice were euthanized after 28-d inoculation.

    Click to Show/Hide
Response regulation Circ_0000190 overexpression inhibited the proliferation, migration and invasion and promoted Erastin- or ras selective lethal 3 (RSL3)-mediated ferroptosis in gastric cancer cells. And circ_0000190 suppressed GC progression via miR-382-5p-dependent regulation of ZNRF3.
Lidocaine [Investigative]
In total 2 item(s) under this drug
Experiment 1 Reporting the Ferroptosis-centered Drug Response [1]
Drug for Ferroptosis Inducer
Response Target Cystine/glutamate transporter (SLC7A11) Driver; Suppressor
Responsed Disease Breast cancer ICD-11: 2C60
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Apoptosis hsa04210
Cell Process Cell ferroptosis
Cell apoptosis
Cell proliferation
Cell migration
Cell invasion
In Vitro Model
SK-OV-3 cells Ovarian serous cystadenocarcinoma Homo sapiens CVCL_0532
T-47D cells Invasive breast carcinoma Homo sapiens CVCL_0553
In Vivo Model
SPF-level male nude mice aged 56weeks and weighted around 20 g were purchased from Vitalriver (China). All mice were maintained in a 12-hour circadian rhythm, and had free access to water and food. Cancer cells were subcutaneously injected into the right flank of mice. Lidocaine was administrated to mice at a dose of 1.5 mg per kg injected through the vail tails. For control group, the mice were treated with saline. Tumor volume and mice body weight were monitored every 5 days.

    Click to Show/Hide
Response regulation The ovarian and breast cancer cell proliferation was suppressed while cell apoptosis was induced by lidocaine in vitro. Lidocaine attenuated invasion and migration of ovarian and breast cancer cells as well. Regarding the mechanism, lidocaine downregulated solute carrier family 7 member 11 (SLC7A11) expression by enhancing microRNA-382-5p (miR-382-5p) in the cells.
Experiment 2 Reporting the Ferroptosis-centered Drug Response [1]
Drug for Ferroptosis Inducer
Response Target Cystine/glutamate transporter (SLC7A11) Driver; Suppressor
Responsed Disease Ovarian cancer ICD-11: 2C73
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Apoptosis hsa04210
Cell Process Cell ferroptosis
Cell apoptosis
Cell proliferation
Cell migration
Cell invasion
In Vitro Model
SK-OV-3 cells Ovarian serous cystadenocarcinoma Homo sapiens CVCL_0532
T-47D cells Invasive breast carcinoma Homo sapiens CVCL_0553
In Vivo Model
SPF-level male nude mice aged 56weeks and weighted around 20 g were purchased from Vitalriver (China). All mice were maintained in a 12-hour circadian rhythm, and had free access to water and food. Cancer cells were subcutaneously injected into the right flank of mice. Lidocaine was administrated to mice at a dose of 1.5 mg per kg injected through the vail tails. For control group, the mice were treated with saline. Tumor volume and mice body weight were monitored every 5 days.

    Click to Show/Hide
Response regulation The ovarian and breast cancer cell proliferation was suppressed while cell apoptosis was induced by lidocaine in vitro. Lidocaine attenuated invasion and migration of ovarian and breast cancer cells as well. Regarding the mechanism, lidocaine downregulated solute carrier family 7 member 11 (SLC7A11) expression by enhancing microRNA-382-5p (miR-382-5p) in the cells.
References
Ref 1 Lidocaine Promoted Ferroptosis by Targeting miR-382-5p /SLC7A11 Axis in Ovarian and Breast Cancer. Front Pharmacol. 2021 May 26;12:681223. doi: 10.3389/fphar.2021.681223. eCollection 2021.
Ref 2 Circ_0000190 sponges miR-382-5p to suppress cell proliferation and motility and promote cell death by targeting ZNRF3 in gastric cancer. J Biochem. 2022 Jan 14:mvac003. doi: 10.1093/jb/mvac003. Online ahead of print.